Pharmaceuticals

President Trump's 100% tariff on imported drugs aims to secure the US supply chain, but the policy's success may hinge on unproven and unverified players.

Biopharma firm GENFIT sees soaring Iqirvo sales and a cash runway past 2028, overshadowing a net loss driven by strategic, non-cash write-downs.

A major lab expansion in Massachusetts aims to slash preclinical timelines for the most promising new cancer treatments, including advanced radiotherapies.

Taiwan's PharmaEssentia is building a new U.S. facility in Puerto Rico, a move set to bolster drug supply chains and deepen US-Taiwan economic ties.

As a critical FDA drug safety reporting deadline looms, a new cloud tool helps smaller biotech and pharma firms avoid costly penalties and level the field.

Clinical AI launches MAIA™ on Google Cloud Marketplace, using Gemini AI to solve the patient enrollment crisis that stalls 80% of medical studies.

A new tool reveals how a federal drug program may be inflating healthcare costs for businesses, intensifying the debate over transparency and reform.

A $10M investment from BVF Partners propels Entera Bio’s revolutionary oral osteoporosis drug into a pivotal Phase 3 trial, a major step for patients.

A pivotal clinical trial for PMM2-CDG, a devastating genetic disorder with no approved treatments, has completed enrollment, offering hope to thousands.

Century Health and VCU are building a massive AI-driven database to decode steatotic liver disease, a silent epidemic affecting nearly 2 billion people.

After 40 years as a silent partner to global brands, Intercon Chemical is launching its own high-stakes medical cleaning lines to meet new safety standards.

A new Concord research center combines patient care and clinical trials, promising to speed up breakthroughs for complex heart, kidney, and metabolic diseases.

A novel triple-action topical spray for male pattern baldness enters a pivotal clinical trial, potentially disrupting a multi-billion dollar market.

Lipocine's stock plummets after its PPD drug fails a Phase 3 trial, but a promising signal in a patient subset offers a narrow path forward.

AvenCell has dosed the first patient with AVC-203, a novel allogeneic CAR-T therapy, aiming to make advanced cancer treatment more accessible and effective.

Scientists propose a unifying model combining 'viral mimicry' and 'cancer dark matter,' potentially revolutionizing how our immune system recognizes and fights tumors.

Indian pharma giant Lupin acquires European ophthalmology specialist VISUfarma, gaining a major foothold in a market fueled by an aging population.

With key hires from Flatiron and Syneos, Target RWE signals major scaling plans in the booming real-world evidence market under new ownership.

With a new patent for its drug ALPHA-1062, Alpha Cognition may become a first-mover in the $14 billion traumatic brain injury market, which has no approved therapies.

A new partnership aims to simplify pharmacy savings by combining a navigation hub with an AI-powered marketplace, challenging traditional industry models.